Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

898 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. Fiskus W, et al. Among authors: green mr. Leukemia. 2021 Sep;35(9):2621-2634. doi: 10.1038/s41375-021-01181-w. Epub 2021 Mar 2. Leukemia. 2021. PMID: 33654205 Free PMC article.
Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia.
Vicente-Dueñas C, González-Herrero I, Sehgal L, García-Ramírez I, Rodríguez-Hernández G, Pintado B, Blanco O, Criado FJG, Cenador MBG, Green MR, Sánchez-García I. Vicente-Dueñas C, et al. Among authors: green mr. Leukemia. 2019 Jan;33(1):249-278. doi: 10.1038/s41375-018-0192-z. Epub 2018 Jun 28. Leukemia. 2019. PMID: 29955131 Free PMC article. No abstract available.
RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. Mill CP, et al. Among authors: green mr. Blood. 2019 Jul 4;134(1):59-73. doi: 10.1182/blood.2018893982. Epub 2019 Apr 25. Blood. 2019. PMID: 31023702 Free PMC article.
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.
Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR. Jain N, et al. Among authors: green mr. Sci Transl Med. 2019 Jun 19;11(497):eaav5599. doi: 10.1126/scitranslmed.aav5599. Sci Transl Med. 2019. PMID: 31217338 Free PMC article.
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Mondello P, et al. Among authors: green mr. Cancer Discov. 2020 Mar;10(3):440-459. doi: 10.1158/2159-8290.CD-19-0116. Epub 2020 Jan 8. Cancer Discov. 2020. PMID: 31915197 Free PMC article.
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.
Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Deng Q, et al. Among authors: green mr. Nat Med. 2020 Dec;26(12):1878-1887. doi: 10.1038/s41591-020-1061-7. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020644 Free PMC article.
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Fiskus W, et al. Among authors: green mr. Blood Cancer J. 2021 May 20;11(5):98. doi: 10.1038/s41408-021-00487-3. Blood Cancer J. 2021. PMID: 34016956 Free PMC article.
898 results